10.05.2024  22:00:00 Zm. -1,0900 Wolumen Bid22:49:24 Ask22:49:24 Kapitalizacja Rynkowa St. dywidendy Wskaźnik C/Z
127,0500USD -0,85% 1,69 mln
Obrót: 160,89 mln
126,5000Wolumen Bid: 300 129,5000Wolumen Ask: 300 50,53 mldUSD - 90,75

Opis działalności

Dexcom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world.
 

Zarząd & Rada nadzorcza

CEO
Kevin Sayer
Zarząd
Jereme Sylvain, Andrew K. Balo, Barry Regan, Chad Patterson, Don Abbey, Jake Leach, Paul Flynn, Sadie Stern, Shelly Selvaraj, Steven R. Pacelli, Sumi Shrishrimal
Rada nadzorcza
Kevin Sayer, Barbara E. Kahn, Bridgette Heller, Eric J. Topol, M.D., Jay Skyler, M.D., Karen Dahut, Kyle Malady, Mark Foletta, Nick Augustinos, Richard Collins, Steven R. Altman
 

Dane firmy

Nazwa: Dexcom Inc.
Adres: 6340 Sequence Drive,San Diego, CA 92121, USA
Telefon: +1-858-200-0200
Fax: -
E-mail: -
Internet: https://www.dexcom.com/
Przemysł: Biotechnologia
Sektor: Biotechnologia
Podsektor: Biotechnologia
Koniec roku finansowego: 31.12
Free float: -
Data IPO: -

Relacje inwestorskie

Nazwa: Steve Pacelli
Telefon: -
Fax: -
E-mail: spacelli@dexcom.com

Główni akcjonariusze

Inne
 
55,44%
Vanguard Group Inc
 
11,42%
Blackrock Inc.
 
8,57%
Baillie Gifford and Company
 
4,31%
State Street Corporation
 
4,27%
Sands Capital Management, LLC
 
3,38%
JP Morgan Chase & Company
 
3,27%
FMR, LLC
 
2,73%
Capital Research Global Investors
 
2,35%
Inne
 
4,26%